FDA approves DreaMed’s diabetes software for personalized insulin recommendations | FierceBiotech
Jun 19, 2018 @ 8:05

The FDA granted a de novo marketing authorization for DreaMed Diabetes’ decision support software, which assists healthcare providers with the treatment of Type 1 diabetes patients that use insulin pumps and continuous glucose monitoring.

Sourced through Scoop.it from: www.fiercebiotech.com

Leave a Reply